{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:13:01Z","timestamp":1770070381835,"version":"3.49.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the incidence and factors associated with SLE flares following HCQ discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective single-centre study of adult SLE patients who discontinued HCQ. Clinical and serological characteristics at baseline (time of HCQ discontinuation) were compared between patients who experienced flares (any, repeated or severe) and those who remained flare-free during the follow-up, with a potential observation period of up to 36\u2009months. Categorical variables were analysed using Fisher\u2019s exact test; continuous variables using appropriate tests based on normality and variance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 42 patients included, 12 (29%), 15 (36%) and 14 (38%) experienced a flare during the first, second and third year, respectively. Over 36\u2009months, 21 (50%) had at least one flare, 10 had a severe flare and eight had repeated flares. Nineteen patients remained flare-free. Low C3 levels at baseline were associated with any flare (P\u2009&amp;lt;\u20090.001), repeated flares (P\u2009&amp;lt;\u20090.001) and severe flares (P\u2009=\u20090.014) compared with those without flares. Patients with low C3 at baseline flared earlier and more frequently (log-rank P\u2009&amp;lt;\u20090.001) with hazard ratio of 10.18 (95% CI: 3.26\u201331.84, P\u2009&amp;lt;\u20090.001) for flaring, compared with those with normal C3. Other clinical and laboratory factors were not associated with flare prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>50% of patients who discontinued HCQ flared within 2\u2009years. Low C3 levels at baseline were associated with increased risk of flares. These findings suggest that flares are common soon after HCQ discontinuation, and low C3 may help identify patients at higher risk for disease reactivation after HCQ discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf498","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:09:13Z","timestamp":1757678953000},"source":"Crossref","is-referenced-by-count":0,"title":["Hydroxychloroquine discontinuation in SLE: a retrospective cohort study with 3-year follow-up"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9180-9170","authenticated-orcid":false,"given":"Milena","family":"Delai","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Beth Israel Deaconess Medical Center , Boston, MA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3589-8081","authenticated-orcid":false,"given":"Rachel B","family":"Simon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Beth Israel Deaconess Medical Center , Boston, MA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3353-2831","authenticated-orcid":false,"given":"Eduardo M","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Beth Israel Deaconess Medical Center , Boston, MA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-3826","authenticated-orcid":false,"given":"Vasileios C","family":"Kyttaris","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Beth Israel Deaconess Medical Center , Boston, MA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"key":"2026020205390445000_keaf498-B1","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"2026020205390445000_keaf498-B2","doi-asserted-by":"crossref","first-page":"1759720X211073001","DOI":"10.1177\/1759720X211073001","article-title":"Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge","volume":"14","author":"Dima","year":"2022","journal-title":"Ther Adv Musculoskelet"},{"key":"2026020205390445000_keaf498-B3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/eji.202149361","article-title":"Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells","volume":"52","author":"Cenac","year":"2022","journal-title":"Eur J Immunol"},{"key":"2026020205390445000_keaf498-B4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026020205390445000_keaf498-B5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study","volume":"10","author":"Levy","year":"2001","journal-title":"Lupus"},{"key":"2026020205390445000_keaf498-B6","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2006.068676","article-title":"Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L)","volume":"66","author":"Alarc\u00f3n","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2026020205390445000_keaf498-B7","first-page":"965","article-title":"[Long-term effects of hydroxychloroquine on metabolism of serum lipids and left ventricular structure and function in patients of systemic lupus erythematosus]","volume":"94","author":"Meng","year":"2014","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2026020205390445000_keaf498-B8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026020205390445000_keaf498-B9","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3899\/jrheum.170645","article-title":"More consistent antimalarial intake in first 5 years of disease is associated with better prognosis in patients with systemic lupus erythematosus","volume":"45","author":"Pakchotanon","year":"2018","journal-title":"J Rheumatol"},{"key":"2026020205390445000_keaf498-B10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026020205390445000_keaf498-B11","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026020205390445000_keaf498-B12","volume-title":"StatPearls","author":"Stokkermans","year":"2025"},{"key":"2026020205390445000_keaf498-B13","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"2026020205390445000_keaf498-B14","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.2022.13591","article-title":"Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares","volume":"328","author":"Jorge","year":"2022","journal-title":"JAMA"},{"key":"2026020205390445000_keaf498-B15","author":"Lim","year":"2024"},{"key":"2026020205390445000_keaf498-B16","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","author":"Canadian Hydroxychloroquine Study Group","year":"1991","journal-title":"N Engl J Med"},{"key":"2026020205390445000_keaf498-B17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1191\/096120398678919778","article-title":"A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus","volume":"7","author":"Tsakonas","year":"1998","journal-title":"Lupus"},{"key":"2026020205390445000_keaf498-B18","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2026020205390445000_keaf498-B19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1191\/096120399680411281","article-title":"Classification and definition of major flares in SLE clinical trials","volume":"8","author":"Petri","year":"1999","journal-title":"Lupus"},{"key":"2026020205390445000_keaf498-B20","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"},{"key":"2026020205390445000_keaf498-B21","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/rheumatology\/kez422","article-title":"Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission","volume":"59","author":"Zen","year":"2020","journal-title":"Rheumatology"},{"key":"2026020205390445000_keaf498-B22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/rheumatology\/keab373","article-title":"Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis","volume":"61","author":"Zen","year":"2022","journal-title":"Rheumatology"},{"key":"2026020205390445000_keaf498-B23","first-page":"S75","article-title":"What happens after complete withdrawal of therapy in patients with lupus nephritis","volume":"31","author":"Moroni","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2026020205390445000_keaf498-B24","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1136\/annrheumdis-2022-222435","article-title":"Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial","volume":"81","author":"Jourde-Chiche","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026020205390445000_keaf498-B25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","article-title":"Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial","volume":"79","author":"Mathian","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026020205390445000_keaf498-B26","doi-asserted-by":"crossref","first-page":"e000841","DOI":"10.1136\/lupus-2022-000841","article-title":"Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus","volume":"10","author":"Fasano","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2026020205390445000_keaf498-B27","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1093\/rheumatology\/kead306","article-title":"Subtherapeutic hydroxychloroquine concentration is associated with increased disease activity and greater organ damage in lupus","volume":"63","author":"Kang","year":"2024","journal-title":"Rheumatology"},{"key":"2026020205390445000_keaf498-B28","doi-asserted-by":"crossref","first-page":"SI114","DOI":"10.1093\/rheumatology\/kead647","article-title":"Impact of serological activity on flare following clinically inactive disease and remission in childhood-onset systemic lupus erythematosus","volume":"63","author":"Kisaoglu","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205390445000_keaf498-B29","doi-asserted-by":"crossref","first-page":"e001434","DOI":"10.1136\/lupus-2024-001434","article-title":"Comparison of flares in 85 patients with SLE who maintained, discontinued or reduced dose of hydroxychloroquine during a prospective study of ophthalmological screening for retinopathy (PERFOCTAPS Study)","volume":"12","author":"Marques Dias","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026020205390445000_keaf498-B30","doi-asserted-by":"crossref","first-page":"105756","DOI":"10.1016\/j.jbspin.2024.105756","article-title":"Risk of flare in patients with SLE in remission after hydroxychloroquine or chloroquine withdrawal","volume":"91","author":"Trefond","year":"2024","journal-title":"Joint Bone Spine"},{"key":"2026020205390445000_keaf498-B31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-020-02282-0","article-title":"Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study","volume":"22","author":"Fernandez-Ruiz","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026020205390445000_keaf498-B32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","article-title":"Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Almeida-Brasil","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf498\/64273383\/keaf498.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf498\/64273383\/keaf498.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf498\/64273383\/keaf498.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:39:11Z","timestamp":1770028751000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf498\/8254284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf498","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,15]]},"article-number":"keaf498"}}